“…In general, APOE 4 and its association with different measurable clinical variables such as dementia severity [84], neuropsychological scores [85], pathology burdens [86], cortical morphometry [5], morphometric-MRI [87,88], functional-MRI [89–91], electroencephalographic (EEG) [92,93] and magnetoencephalographic (MEG) signals [94], evoked potentials (EPs) changes [95,96], and other methods [97] has been investigated much more extensively than APOE 2 [98–100]. In fact, studies focusing on APOE 2 and its association to different clinical and subclinical parameters and possible molecular mechanisms of brain protection have been historically, less numerous than investigations comparing APOE 4 vs. APOE 3 for example.…”